Albany, NY -- (SBWIRE) -- 10/13/2017 -- Umbilical cord blood (UCB) is collected from the umbilical cord of a newborn baby and also retrieved from the placenta after delivery. It is enriched with adult stem cells and these stem cells play a vital role in regulating all biological activities and in developing tissues in the human body. Many types of stem cells are present in UCB including hematopoietic stem cells and mesenchymal stem cells. Hematopoietic stem cells give rise to all the other blood cells. Hematopoietic stem cells are severely damaged in people suffering from bone marrow diseases, malignancies, inherited metabolic disorders, and immunological disorders. Mesenchymal stem cells are involved in the development of tissues such as cartilage, bone, fat, new blood vessels, and cardiac muscles.

UCB is used in clinical procedures associated with regenerative medicines. For instance, UCB-derived stem cells are used in hematopoietic stem cell transplantation (HSCT) for the treatment of life-threatening diseases such as leukemia and type I diabetes in children and adults. In addition, UCB is also used in the treatment of diseases such as bone marrow disorders, circulatory diseases, heart problems, neurological diseases, and cartilage disorders.

Get The Sample Copy Of Report: https://www.marketresearchreports.biz/sample/sample/320897

Globally, increasing prevalence of chronic diseases coupled with the emerging field of regenerative medicines is driving the UCB banking market. In addition, various government associations and initiatives are also supporting in the growth of the UCB banking market.

However, strict license and accreditation procedures impede the growth of UCB banking market. In addition, high banking cost in private UCB banks is also hampering the growth of UCB banking market. Allogeneic hematopoietic stem cell transplantation and cord tissue storage are some of the major trends in UCB banking market.

North America has the largest market for UCB banking. The U.S., followed by Canada, is the largest market for UCB banking in the region. Increasing prevalence of chronic diseases is the key driver of the UCB banking market. In addition, initiatives by various government associations have also led to the increase in awareness about the importance of cord blood donation in the region.

In Europe, the UCB banking market is growing due to increased awareness about potential applications of cord blood in the treatment of life-threatening diseases. In addition, increasing number of live births is also playing a vital role in the growth of UCB banking market in Europe. For instance, according to Eurostat, in 2010, 807,271 live births registered in 2010 and the number reached to 812,970 by 2013 in the U.K.. Due to increased awareness about potential of cord blood, newborns family donates and preserves cord blood either in private or public banks in Europe.

Send An Enquiry : https://www.marketresearchreports.biz/sample/enquiry/320897

However, Asia-Pacific is the fastest growing region in the UCB banking market. This is due to increasing prevalence of chronic diseases in the region. In addition, raising awareness about potential applications of cord blood and increasing number of live births are also contributing in the growth of UCB banking market in the region. China has the highest number of live births, followed by India around the world.

The report provides in-depth analysis and estimation of the UCB market from 2014 to 2020, considering 2014 as the base year for calculation. Additionally, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.

Some of the major players operating in the UCB banking market:

Cord Blood Registry Systems, Inc.
Cordlife Group Limited.
Cord Blood America, Inc.
NeoStem Inc.
Cryo-Cell International, Inc.
ViaCord.
Esperite NV.
Smart Cells International Ltd.
China Cord Blood Corporation.
Other

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Report Methodology
1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porters Five Forces Analysis
3.1 Bargaining Power of Suppliers
3.2 Bargaining Power of Buyers
3.3 Threat of New Entrants
3.4 Threat of Substitutes
3.5 Intensity of Rivalry

Chapter 4 Industry overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 Increasing prevalence of chronic diseases enhances the market growth
4.2.2 Emerging field of regenerative medicines boost the market growth
4.2.3 Initiatives by various government associations have increased the importance of UCB
4.3 Impact Analysis of Market Drivers
4.4 Market Restraints
4.4.1 Strict license and accreditation procedures impede the market growth
4.4.2 High cord blood banking fee in private UCB banks
4.5 Impact Analysis of Market Restraints
4.6 Market Tends
4.6.1 UCB is gaining popularity in allogeneic hematopoietic stem cell transplantation
4.6.2 Umbilical cord tissue storage is gaining importance in UCB banking market

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Therapeutic Application of UCB
6.1 Leukemia
6.2 Bone Marrow Failure Syndrome
6.3 Metabolic/Storage Diseases
6.4 Lymphoma
6.5 Immune Deficiencies

Chapter 7 Market Size and Forecast by Storage Option
7.1 Private UCB Banks
7.2 Public UCB Banks

Chapter 8 Market Size and Forecast by Geography
8.1 North America
8.1.1 Scenario in the U.S.
8.1.1.1 Legislations
8.1.2 Scenario in Canada
8.2 Europe
8.2.1 Scenario in the U.K.
8.2.1.1 Legislations
8.2.2 Scenario in France
8.2.3 Scenario in the Germany
8.2.4 Scenario in Spain
8.2.5 Scenario in Italy
8.2.6 Scenario in Belgium
8.3 Asia Pacific
8.3.1 Scenario in China
8.3.2 Scenario in India
8.3.3 Scenario in Japan
8.3.4 Scenario in Australia
8.3.5 Scenario in Singapore

Request to Buy This Report : https://www.researchmoz.com/checkout?rep_id=320897&licType=S

Chapter 9 Competitive Scenario
9.1 Competitive Benchmarking

Chapter 10 Company Profiles
10.1 Cord Blood Registry Systems, Inc.
10.1.1 Company overview
10.1.2 Products and services
10.1.3 Financial performance
10.1.4 Recent developments
10.2 Cordlife Group Limited
10.2.1 Company overview
10.2.2 Products and services
10.2.3 Financial performance
10.2.4 Recent developments
10.3 Cord Blood America, Inc.
10.3.1 Company overview
10.3.2 Products and services
10.3.3 Financial performance
10.3.4 Recent developments
10.4 NeoStem, Inc.
10.4.1 Company overview
10.4.2 Products and services
10.4.3 Financial performance
10.4.4 Recent developments
10.5 Cryo-Cell International, Inc.
10.5.1 Company overview
10.5.2 Products and services
10.5.3 Financial performance
10.5.4 Recent developments
10.6 ViaCord
10.6.1 Company overview
10.6.2 Products and services
10.6.3 Financial performance
10.6.4 Recent developments
10.7 Esperite N.V.
10.7.1 Company overview
10.7.2 Products and services
10.7.3 Financial performance
10.7.4 Recent developments
10.8 StemCyte
10.8.1 Company overview
10.8.2 Products and services
10.8.3 Financial performance
10.8.4 Recent Developments
10.9 Smart Cells International, Ltd.
10.9.1 Company overview
10.9.2 Products and services
10.9.3 Financial performance
10.9.4 Recent developments
10.10 China Cord Blood Corporation
10.10.1 Company overview
10.10.2 Products and Services
10.10.3 Financial performance
10.10.4 Recent developments